The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech, which may offer quicker production and greater efficacy than ...

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

FluMist is the only nasal flu vaccine, but it is not new. The FDA approved it in 2003 for people 5 to 49 years old before ...

In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives The trial did not meet one of its ...

The Food and Drug Administration approved an updated coronavirus vaccine manufactured by Novavax Friday, days after new mRNA coronavirus vaccines manufactured by Pfizer-BioNTech and Moderna ...

The revamped vaccine is an effort by regulators and vaccine makers to keep pace with the virus, which continues to evolve ...

Influenza vaccine: Everyone 6 months and older The ... Two mRNA vaccines are available, one by Moderna and one by Pfizer-BioNTech. Both are recommended for everyone 6 months and older, including ...

Discover the significant differences in influenza and COVID-19 vaccination rates among children receiving long-term ...

Pfizer/BioNTech's combination vaccine faced setbacks ... including an enhanced influenza vaccine in adults 65 years and older." Primary Endpoint Higher immune responses against influenza and ...

Germany's BioNTech and US pharma giant Pfizer said Friday they had suffered a setback in a late-stage trial of their combined mRNA vaccine against COVID-19 and influenza. Typically, influenza is ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...

Epidemiologists and a federal health agency have criticized new COVID-19 guidance from Florida Surgeon General Joseph Ladapo ...